Back to Encyclopedia

Klow Blend (KPV + LL-37 / TB-500 + BPC-157 + GHK-Cu)

Peptide Blends

Also known as: Klow Stack, Gut + Skin Stack, KPV / GHK-Cu / BPC / TB-500 Combo, KLOW

Half-life: KPV ~minutes; BPC-157 ~4 h; TB-500 ~6-8 h; GHK-Cu ~minutes systemically

Last reviewed:  ·  Published:

HealingAnti InflammatoryAnti AgingGut Health

Overview

The Klow Blend is a four-peptide research formulation that adds KPV (Lys-Pro-Val) to the Glow trio. The "K" in Klow refers to KPV, an alpha-MSH C-terminal tripeptide with potent anti-inflammatory activity that complements the existing GHK-Cu + BPC-157 + TB-500 framework. The most common version sold by UK suppliers (and the one this article is anchored to) totals roughly 80 mg of peptide across the four components: 50 mg GHK-Cu, 10 mg KPV, 10 mg BPC-157, and 10 mg TB-500.

The intent of the stack is to layer KPV's NF-κB suppression on top of the existing healing and cosmetic mechanisms — giving the user a broader anti-inflammatory ceiling while keeping all of the soft-tissue and skin benefits of the Glow Blend. KPV is particularly well-studied in inflammatory bowel disease models and on inflamed-skin conditions, so the Klow Blend is favoured by people running it for systemic inflammation, gut-skin axis issues (rosacea, eczema flares), or stubborn dermatological recovery after the basic Glow stack has plateaued.

No published clinical studies exist of the four-peptide formulation. The evidence base is entirely component-by-component. All four peptides are unapproved research chemicals globally; BPC-157 and TB-500 are prohibited by WADA. Sold as a single lyophilised vial intended for one-step reconstitution.

History

KPV was characterised as the active C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH) in the late 1990s and early 2000s, with research groups demonstrating its anti-inflammatory activity in colitis and dermatitis models. GHK-Cu, BPC-157, and TB-500 each have their own decades-long research histories (see component articles).

The "Klow Stack" naming convention emerged on peptide-research forums around 2022-2024, following the popularity of the simpler "Glow" three-peptide blend. UK research-chemical suppliers (notably my-peptides.co.uk) began co-packaging the four-peptide formulation in single vials in 2024-2025 to simplify dosing for users who had previously been juggling four separate reconstitutions and injection schedules.

Effects

  • Broad anti-inflammatory action across NF-κB, nitric oxide, and copper-modulation pathways
  • Soft-tissue healing and tendon recovery (BPC + TB contribution)
  • Stimulates collagen synthesis and skin elasticity (GHK-Cu contribution)
  • Anti-inflammatory action in the gut and inflamed skin (KPV contribution)
  • Modulates the gut-skin axis (anecdotal, component-derived)
  • Reduces scar formation and supports remodelling
  • Promotes angiogenesis and improved blood flow to repair sites

Side Effects

  • Injection site irritation (occasionally with mild bluish tint from copper)
  • Temporary lightheadedness
  • Mild lethargy in first 1-2 weeks
  • Headache
  • Nausea at upper dosing range
  • Possible flushing from MSH-pathway activity (KPV)

Tolerability

Each component is well tolerated individually. KPV in particular has a clean safety profile across published colitis and dermatitis studies. Side effects from the blend are the union of those for each component — most commonly injection-site reactions, transient lightheadedness, and occasional flushing. People with copper sensitivity, Wilson's disease, or active melanoma should avoid this stack (the copper component and any MSH-axis activity warrant caution). No safety data exists for the combined four-peptide blend at clinical-trial standard.

Dosing Ranges

Inflammation + recovery loading

Dose Range

500 mcg KPV + 250 mcg BPC + 2 mg TB-500 + 1-2 mg GHK-Cu

Frequency

KPV + BPC + GHK daily, TB-500 twice weekly

Duration

6-8 weeks

Gut-skin axis protocol

Dose Range

500 mcg KPV + 250 mcg BPC + 1 mg TB-500 + 1 mg GHK-Cu

Frequency

Daily, with TB-500 weekly

Duration

8-12 weeks

Maintenance

Dose Range

500 mcg KPV + 250 mcg BPC + 1 mg TB-500 + 1 mg GHK-Cu

Frequency

KPV + BPC 3-4x weekly, others weekly

Duration

Ongoing cycles

Dosing information is for educational purposes only. Consult a healthcare professional before using any peptide.

Reconstitution

Preparation Details

Typical Vial Size

80 mg

Water Type

Bacteriostatic water (BAC water)

Mixing Volume

3 mL

Half-Life

KPV ~minutes; BPC-157 ~4 h; TB-500 ~6-8 h; GHK-Cu ~minutes systemically

Molecular Weight

Blend (combined 4 peptides)

Co-packaged 80 mg vials are typically reconstituted with 3 mL BAC water — GHK-Cu dominates the volume due to its 50 mg loading. Per-component dosing varies wildly across the four peptides; use the calculator carefully. Store refrigerated at 2-8°C and protect from light. Use within 28 days.

Calculate Klow Blend (KPV + LL-37 / TB-500 + BPC-157 + GHK-Cu) dose

Where to buy Klow Blend (KPV + LL-37 / TB-500 + BPC-157 + GHK-Cu)

Affiliate links
Ships to:

Disclosure: PinnyPeptide may earn a commission on purchases made through the links above, at no extra cost to you. We only list vendors we're willing to point our community at, but inclusion is not a clinical endorsement. Always verify each vendor's third-party testing and your local legal status before purchasing.

Regulatory Status

FDA Status

No component FDA approved for human use. FDA issued a warning letter in 2024 regarding compounded BPC-157 products.

Legal Status

All four components are unregulated research chemicals. BPC-157 and TB-500 prohibited by WADA. KPV not specifically scheduled but unapproved.

USA

Not approved

FDA warning on BPC-157 compounded products; other components unapproved

EU

Not approved

Not authorized as medicinal products

UK

Not approved

All four classified as research chemicals

Australia

Not approved

TB-500 banned in racing; remaining components not evaluated

Russia

Not approved

Available as research compounds

Canada

Not approved

Health Canada has not authorized injectable forms

Cited Studies

The tripeptide feG ameliorates systemic inflammatory responses

Dalli J, Norling LV, Renshaw D, Cooper D, Leung KY, Perretti M

Blood (2008)

Background reference: short MSH-derived tripeptides modulate inflammation systemically — supports the mechanistic rationale for KPV's anti-inflammatory contribution.

View Study →

GHK-Cu may Prevent Oxidative Stress in Skin by Regulating Copper and Modifying Expression of Numerous Antioxidant Genes

Pickart L, Vasquez-Soltero JM, Margolina A

Cosmetics (2015)

Component review: GHK-Cu modulates antioxidant gene expression and contributes to skin regeneration — the mechanistic basis for the cosmetic component.

View Study →

Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts

Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH

Molecules (2014)

Component study: BPC-157 upregulates GH receptor expression in tendon fibroblasts — basis for the tendon-healing contribution.

View Study →

Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair

Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D

Nature (2004)

Component study: Thymosin Beta-4 (parent of TB-500) promotes cell migration and survival in injury repair.

View Study →

Compare Klow Blend (KPV + LL-37 / TB-500 + BPC-157 + GHK-Cu) with

Track Klow Blend (KPV + LL-37 / TB-500 + BPC-157 + GHK-Cu) and more with PinnyPeptide.

Sign Up to Track Klow Blend (KPV + LL-37 / TB-500 + BPC-157 + GHK-Cu)

Free forever · defaults pre-filled from this article